RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can improve on this by refining lung cancer risk, stratifying positive CT scans & categorizing intermediate-risk pulmonary nodules.
RT @OncimmuneECDT: "Biomarkers are playing an emerging role in the early detection of #lungcancer. There are many potential roles for #biom…
RT @OncimmuneECDT: "Biomarkers are playing an emerging role in the early detection of #lungcancer. There are many potential roles for #biom…
RT @OncimmuneECDT: "Biomarkers are playing an emerging role in the early detection of #lungcancer. There are many potential roles for #biom…
"Biomarkers are playing an emerging role in the early detection of #lungcancer. There are many potential roles for #biomarkers, from risk stratification to classification of nodules detected incidentally or through low-dose screening programs." @CEBP_AACR
RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
RT @NCICastle: Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can imp…
RT @NCIprevention: More from the #EDRN issue of @CEBP_AACR #LCSM https://t.co/5lzijWtliD
More from the #EDRN issue of @CEBP_AACR #LCSM
Effectiveness of lung cancer screening is limited by use in high-risk populations & many false positives. Biomarkers can improve on this by refining lung cancer risk, stratifying positive CT scans & categorizing intermediate-risk pulmonary nodules.